Skip to main content

Oncolytics Biotech Inc.

corporate_fare Company Profile

Oncolytics Biotech Inc.

ONCY·NASDAQ·Life Sciences·CIK 0001129928

We are a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA ("dsRNA") virus. It selectively replicates in RAS-mutated tumors, activating the innate and adaptive immune systems and weakening tumor defense mechanisms. This process improves the immune system's ability to fight cancer, making tumors more susceptible to various oncology treatments. Pelareorep has demonstrated promising results in changing the tumor microenvironment ("TME") to be more immunologically favorable, which makes the tumor more susceptible to treatment combinations. These combinations include chemotherapies, checkpoint inhibitors ("CPIs"), and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. Pelareorep induces tumor-reactive T cells, helps these cells infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1/PD-L1. The company has not been profitable since its inception and expects to continue incurring substantial losses as research and development efforts continue. Significant revenues are not expected until pelareorep becomes commercially viable.

Oncolytics Biotech Inc. (NASDAQ:ONCY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for ONCY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ONCY spans 10-Q, 8-K.

Recent high-impact activity:

  • Oncolytics Q3: $2.4M Cash, Going-Concern Doubt, Nasdaq Bid-Price Notice
  • Pelareorep Shows Durable Survival Benefit in Anal Cancer, Oncolytics Says
  • Oncolytics Expects Interim REO 033 Data by Year-End; FDA Aligns on Accelerated Approval Path
  • Oncolytics Nears Full Site Activation in Colorectal Cancer Trial, Eyes Year-End Interim Data
  • FDA Aligns With Oncolytics on Registrational Path for Colorectal Cancer Drug

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$28.76M
Diluted EPS
-$0.30
Op. Cash Flow
-$20.11M
Free Cash Flow
-$20.12M
Operating Income
-$28.73M
Cash & Equivalents
$5.2M
Debt / Equity
0.00×
Shares Outstanding
108.02M sh
Source: 10-K · filed 2026-03-30 · accession 0001129928-26-000020

Short Interest & Short Volume

9.91 days to cover

FINRA reported short interest of 8,679,124 shares in ONCY as of the October 30, 2026 settlement, a 3.8% decrease from the prior period — about 9.9 days to cover at its recent average daily volume. On November 20, 2026, 58.5% of ONCY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,679,124 shares as of October 30, 2026
Change vs prior period▼ 3.8%
Days to cover9.91 at avg daily volume of 875,790
Daily short volume (FINRA facilities)58.5% of 850,054 shares on November 20, 2026
5-day average short volume35.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$0.3699 +5.66% today
52-week range · as of 2026-11-13 $0.3363 – $1.3
Market cap
$47.66M
Volume
1.1M (0.8× avg)
3-mo avg 1.4M
Live data · 2026-11-22 08:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ONCY - Latest Insights

ONCY
Nov 13, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.3699 info
Change: -$0.0001 (-0.03%) info
Market Cap: $47.663M info
ONCY
Oct 27, 2026, 10:33 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.462
Real-time Price: $0.3699 info
Change: -$0.0921 (-20%) info
Market Cap: $47.663M info
ONCY
Sep 28, 2026, 9:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6831
Real-time Price: $0.3699 info
Change: -$0.3132 (-46%) info
Market Cap: $47.663M info
ONCY
Sep 28, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6827
Real-time Price: $0.3699 info
Change: -$0.3128 (-46%) info
Market Cap: $47.663M info
ONCY
Aug 18, 2026, 9:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.3699 info
Change: -$0.4629 (-56%) info
Market Cap: $47.663M info
ONCY
Aug 18, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.3699 info
Change: -$0.4629 (-56%) info
Market Cap: $47.663M info
ONCY
Aug 12, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8073
Real-time Price: $0.3699 info
Change: -$0.4374 (-54%) info
Market Cap: $47.663M info
ONCY
Jul 24, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.820
Real-time Price: $0.3699 info
Change: -$0.4501 (-55%) info
Market Cap: $47.663M info
ONCY
Jul 20, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.865
Real-time Price: $0.3699 info
Change: -$0.4951 (-57%) info
Market Cap: $47.663M info
ONCY
Jul 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.9152
Real-time Price: $0.3699 info
Change: -$0.5453 (-60%) info
Market Cap: $47.663M info
ONCY
Jul 13, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.3699 info
Change: -$0.5601 (-60%) info
Market Cap: $47.663M info
ONCY
Jul 13, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $0.3699 info
Change: -$0.5601 (-60%) info
Market Cap: $47.663M info
ONCY
Jul 08, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.799
Real-time Price: $0.3699 info
Change: -$0.4291 (-54%) info
Market Cap: $47.663M info
ONCY
Jun 16, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8774
Real-time Price: $0.3699 info
Change: -$0.5075 (-58%) info
Market Cap: $47.663M info
ONCY
Jun 16, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.8701
Real-time Price: $0.3699 info
Change: -$0.5002 (-57%) info
Market Cap: $47.663M info
ONCY
Jun 02, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.3699 info
Change: -$0.7101 (-66%) info
Market Cap: $47.663M info
ONCY
Jun 01, 2026, 9:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.3699 info
Change: -$0.7585 (-67%) info
Market Cap: $47.663M info
ONCY
Jun 01, 2026, 9:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.3699 info
Change: -$0.7301 (-66%) info
Market Cap: $47.663M info
ONCY
May 22, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.800
Real-time Price: $0.3699 info
Change: -$0.4301 (-54%) info
Market Cap: $47.663M info
ONCY
May 22, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.3699 info
Change: -$0.4401 (-54%) info
Market Cap: $47.663M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets